BAY-85-8501 NEW
| Price | $88 | $223 | $331 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: BAY-85-8501 | CAS No.: 1161921-82-9 |
| Purity: 99.16% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | BAY-85-8501 |
| Description | BAY-85-8501 is a selective, reversible, and potent inhibitor of Human Neutrophil Elastase (HNE) with an IC50 of 65 pM. |
| In vivo | In this study, the exogenous compound HNE noxa is identified as the primary cause of lung injury and hemorrhage. BAY-85-8501 (29), due to its picomolar potency against HNE and high effectiveness against MNE, completely prevents lung injury and subsequent inflammation if administered one hour before exposure to HNE noxa. Despite its high selectivity for HNE inhibition, BAY-85-8501 does not prevent primary lung injury caused by PPE since it has no effect on it. However, BAY-85-8501 can inhibit MNE, an endogenous promoter of inflammation and secondary lung injury, albeit with lower potency. The prevention of inflammation and secondary injury by BAY-85-8501 is less pronounced and requires doses 30 times higher than standard. Its effectiveness primarily relies on its ability to inhibit MNE (Ki=6 nM) in these cases. At a dosage of 0.01 mg/kg, a significant reduction in hemoglobin concentration is noted, and at 0.1 mg/kg, a notable decrease in neutrophil count is observed, indicating efficacy is largely dependent on its potency against HNE (Ki=0.08 nM) in this scenario. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 200 mg/mL (421.53 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (10.54 mM), Sonication is recommended. |
| Keywords | SerineProtease | Serine Protease | Inhibitor | inhibit | HNE | Elastase | BAY-85-8501 | BAY858501 | BAY 85 8501 |
| Inhibitors Related | PMSF | AEBSF hydrochloride | Imidazole | Subtilisin | p-Aminobenzamidine dihydrochloride | Chymotrypsin | Proteinase K | Aprotinin | Ac-Ala-OH | Trypsin | FOY 251 | Benzamidine hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Protease Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1350.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-15 | |
| $2800.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-19 | ||
| $88.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-14 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY